Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|April 26, 2017
Access to Specialty Drugs Remains a Challenge
Author(s)Lauren Santye, Assistant Editor
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses how specialty pharmacies can help patients gain access to costly specialty drug regimens.
Advertisement
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses how specialty pharmacies can help patients gain access to costly specialty drug regimens.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5